Nabriva Therapeutics AG to Post FY2017 Earnings of ($2.13) Per Share, Leerink Swann Forecasts (NBRV)
Nabriva Therapeutics AG (NASDAQ:NBRV) – Analysts at Leerink Swann raised their FY2017 earnings estimates for Nabriva Therapeutics AG in a research report issued on Monday. Leerink Swann analyst P. Matteis now expects that the biotechnology company will post earnings per share of ($2.13) for the year, up from their prior forecast of ($2.16). Leerink Swann currently has a “Outperform” rating and a $22.00 target price on the stock. Leerink Swann also issued estimates for Nabriva Therapeutics AG’s Q4 2017 earnings at ($0.47) EPS and FY2018 earnings at ($2.36) EPS.
Nabriva Therapeutics AG (NASDAQ:NBRV) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($5.83) by $5.29. The business had revenue of $1.05 million during the quarter, compared to analyst estimates of $1.34 million.
TRADEMARK VIOLATION WARNING: “Nabriva Therapeutics AG to Post FY2017 Earnings of ($2.13) Per Share, Leerink Swann Forecasts (NBRV)” was published by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.dailypolitical.com/2017/09/22/nabriva-therapeutics-ag-to-post-fy2017-earnings-of-2-13-per-share-leerink-swann-forecasts-nbrv.html.
Other research analysts also recently issued reports about the stock. Cantor Fitzgerald set a $16.00 price target on shares of Nabriva Therapeutics AG and gave the stock a “buy” rating in a research report on Tuesday, July 11th. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Nabriva Therapeutics AG in a research report on Friday, June 30th. Zacks Investment Research upgraded shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research report on Saturday, May 27th. SunTrust Banks, Inc. started coverage on shares of Nabriva Therapeutics AG in a research report on Friday, August 25th. They issued a “buy” rating and a $20.00 price target on the stock. Finally, Needham & Company LLC restated a “buy” rating and issued a $18.00 price target (up from $15.00) on shares of Nabriva Therapeutics AG in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $19.13.
Nabriva Therapeutics AG (NBRV) opened at 8.35 on Wednesday. Nabriva Therapeutics AG has a 1-year low of $3.52 and a 1-year high of $14.10. The firm has a 50-day moving average of $9.01 and a 200-day moving average of $10.19. The firm’s market capitalization is $224.10 million.
In related news, major shareholder Hbm Healthcare Investments (Ca sold 69,854 shares of the stock in a transaction dated Tuesday, July 18th. The shares were sold at an average price of $10.51, for a total value of $734,165.54. Following the sale, the insider now owns 2,490,952 shares of the company’s stock, valued at approximately $26,179,905.52. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Vivo Capital Viii, Llc acquired 52,631 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The stock was purchased at an average cost of $9.46 per share, for a total transaction of $497,889.26. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 279,000 shares of company stock worth $2,870,869. Corporate insiders own 2.75% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in NBRV. Royal Bank of Canada increased its stake in Nabriva Therapeutics AG by 19.6% during the 2nd quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock valued at $553,000 after buying an additional 8,650 shares during the period. Almanack Investment Partners LLC. increased its stake in Nabriva Therapeutics AG by 482.2% during the 2nd quarter. Almanack Investment Partners LLC. now owns 907,183 shares of the biotechnology company’s stock valued at $1,633,000 after buying an additional 751,366 shares during the period. Nationwide Fund Advisors increased its stake in Nabriva Therapeutics AG by 4.6% during the 2nd quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock valued at $2,032,000 after buying an additional 7,924 shares during the period. Finally, Wellington Management Group LLP increased its stake in Nabriva Therapeutics AG by 9.9% during the 1st quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after buying an additional 193,951 shares during the period. 68.56% of the stock is currently owned by hedge funds and other institutional investors.
About Nabriva Therapeutics AG
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.